 Dalrada Corporation OTCQB:DFCO has reported on the positive results of a second screening study of its patent-pending cerVIA kit used to test for cervical cancer on 100 women in India. The women, aged 31 to 65, were screened with Pap smear and visual inspection with acetic acid VIA using the firms kit and the study revealed VIAs accuracy at 91. 